Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
4.8
Journals
Pharmaceuticals
Special Issues
Advances in the Treatment of Leukemia, Lymphomas and Plasma Cell...
share announcement

Advances in the Treatment of Leukemia, Lymphomas and Plasma Cell Disorders

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (25 April 2026) | Viewed by 5007

Special Issue Editors

Dr. Adriano de Paula Sabino

E-Mail Website
Guest Editor
Laboratório Institucional de Pesquisa em Biomarcadores, Laboratório de Hematologia Clínica, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil
Interests: cancer; leukemia; chemotherapy; biomarkers; genomics; proteomics; metabolomics; nanobiomaterials; regenerative medicine; cell therapy; bioinformatics applied to these fields
Prof. Dr. Karina Braga Gomes

E-Mail Website
Guest Editor
1. Faculty of Medicine, Federal University of Minas Gerais, Professor Alfredo Balena Avenue, 190, Santa Efigênia, Belo Horizonte 30130-100, MG, Brazil
2. Department of Clinical and Toxicological Analyzes, Faculty of Pharmacy, Federal University of Minas Gerais, Presidente Antônio Carlos Avenue, 6627, Pampulha, Belo Horizonte 31270-901, MG, Brazil
Interests: biomarkers of insulin resistance; diabetes; cardiovascular disease and dementia; translational neuroscience
Prof. Dr. Maria Das Graças Carvalho

E-Mail Website
Guest Editor
Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil
Interests: laboratory hematology; hemostasis (thrombin generation tests under different experimental conditions); hemostatic disorders in general (particularly states associated with hypercoagulability)

Special Issue Information

Dear Colleagues,

Leukemia, lymphomas and Plasma Cell Disorders are malignant hematological disorders that have historically posed significant challenges to patients and clinicians. Over the past decades, ongoing research and technological advances have substantially improved diagnostic capabilities, risk stratification, and survival.

Recent developments, including novel agents such as gemtuzumab ozogamicin, blinatumumab, zanabrutinib, and venetoclax, underscore the expanding options for patients with different disease subtypes. Advances in immunotherapy platforms and precision medicine approaches are driving improvements in patient outcomes and quality of life.

This Special Issue aims to collate the latest innovations and clinical insights propelling the field toward more effective treatments and personalized care. We seek to highlight the interplay between novel diagnostic tools, targeted therapeutics, and emerging cellular therapies that will define the future of hematologic oncology. By fostering multidisciplinary collaboration, we hope to accelerate the translation of groundbreaking discoveries into clinical practice.

We invite original research articles, reviews, and clinical studies that explore innovative treatment strategies, translational efforts, and the broader implications of these emerging therapies. Established experts and new hematologic oncology investigators are encouraged to submit their findings.

Dr. Adriano de Paula Sabino
Prof. Dr. Karina Braga Gomes
Prof. Dr. Maria Das Graças Carvalho
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • leukemias
  • lymphomas
  • chemotherapy
  • target therapy
  • immunotherapy
  • kinase inhibitors
  • hematologic oncology
  • therapy
  • treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 2213 KB  
Article
XMU-MP-1, Inhibitor of STE20-like MST1/2 Kinases of the Hippo Signaling Pathway, Suppresses the Cell Cycle, Activates Apoptosis and Autophagy, and Induces Death of Hematopoietic Tumor Cells
by Alexander G. Stepchenko, Sofia G. Georgieva and Elizaveta V. Pankratova
Pharmaceuticals 2025, 18(6), 874; https://doi.org/10.3390/ph18060874 - 12 Jun 2025
Cited by 1 | Viewed by 2025
Abstract
Background/Objectives: Currently, there is limited knowledge on the molecular mechanisms of the “non-canonical” Hippo signaling pathway in hematopoietic tumor cells. We have shown that targeting the MST1/2 kinases, which are the key molecules in this signaling pathway, may be an effective approach [...] Read more.
Background/Objectives: Currently, there is limited knowledge on the molecular mechanisms of the “non-canonical” Hippo signaling pathway in hematopoietic tumor cells. We have shown that targeting the MST1/2 kinases, which are the key molecules in this signaling pathway, may be an effective approach to the treatment of hematologic tumors. Methods: The methods used in this study include cell growth assays, caspase assays, Western blot hybridizations, flow cytometry, and whole-transcriptome analyses. These methods allowed us to better understand the molecular pathways at play. Results: Our results showed that XMU-MP-1, an inhibitor of MST1/2 kinase, specifically reduces the viability of hematopoietic cancer cells but not breast cancer cells. It effectively inhibits the growth of the tumor B- and T-cell lines by blocking cell cycle progression, mainly during the G2/M phase, inducing apoptosis and autophagy. XMU-MP-1 treatment led to increased caspase 3/7 activity and increased levels of the cleaved PARP protein. Levels of the LC3-II protein were also shown to be increased, while the level of p62 decreased. These changes are associated with apoptosis and autophagy, respectively. RNA-seq analysis has demonstrated that XMU-MP-1 suppressed the expression of cell cycle regulators, such as E2F, and cell division cycle genes CDC6,7,20,25,45; cyclins A2,B1,B2, and cyclin-dependent kinases. At the same time, it increased the expression of genes involved in apoptosis, autophagy, and necroptosis. Conclusions: Combinations of growth assays, caspase assays, Western blotting, and RNA-seq have shown that the dramatic reduction in the number of hematopoietic tumor cells after treatment with XMU-MP-1 is due to both cytostatic and cytotoxic effects. The use of MST1/2 kinase inhibitors could be highly promising for complex therapy of hematological tumors. Full article
(This article belongs to the Special Issue Advances in the Treatment of Leukemia, Lymphomas and Plasma Cell Disorders)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 872 KB  
Review
Next-Generation Biomarkers in Multiple Myeloma: Advancing Diagnosis, Risk Stratification, and Precision Therapy Beyond Current Guidelines
by Marta Marques de Carvalho Lopes, Laura do Amaral Xavier, Silvia Cristina Verde Mendes Nolasco, Simone Rodrigues Ribeiro, Danila Felix Coutinho and Adriano de Paula Sabino
Pharmaceuticals 2026, 19(2), 320; https://doi.org/10.3390/ph19020320 - 14 Feb 2026
Viewed by 1286
Abstract
Multiple myeloma (MM) is an oncohematological neoplasm characterized by the abnormal proliferation of neoplastic plasma cells in the bone marrow and the excessive secretion of monoclonal antibodies into the bloodstream. Approximately 3 to 5% of patients present with a variant form of the [...] Read more.
Multiple myeloma (MM) is an oncohematological neoplasm characterized by the abnormal proliferation of neoplastic plasma cells in the bone marrow and the excessive secretion of monoclonal antibodies into the bloodstream. Approximately 3 to 5% of patients present with a variant form of the disease where there is no secretion of monoclonal proteins, characterizing the non-secretory MM picture. It exhibits a highly complex and heterogeneous genetic signature, allowing the disease to be classified into premalignant entities and symptomatic forms. In this context, an integrative narrative review was conducted, encompassing genomic, epigenomic, proteomic, metabolomic, and radiomic biomarkers described in the literature between 2018 and 2025. Emphasis was placed on their translational potential, current limitations in clinical practice, and gaps within recent recommendations. Several categories of biomarkers, particularly ctDNA methylome, single-cell multiomics, proteomics of surface antigens, functional ex vivo assays, and PET/CT radiomics, demonstrate strong potential for enhancing risk stratification, detecting early progression, guiding therapy selection, and identifying novel therapeutic targets. These applications extend beyond existing guideline frameworks. Thus, integrating advanced biomarker platforms can overcome limitations of current diagnostic and therapeutic models and enhance precision strategies across plasma cell disorders. Full article
(This article belongs to the Special Issue Advances in the Treatment of Leukemia, Lymphomas and Plasma Cell Disorders)
►▼ Show Figures

Graphical abstract

11 pages, 1425 KB  
Review
Challenges in the Treatment of HIV-Related Lymphomas Complicated by COVID-19: Case Study and Review of the Literature
by Kinga Siewiorek, Marcin Jasiński, Błażej Izdebski, Maciej Przybylski, Małgorzata Kobylecka, Joanna Mączewska, Krzysztof Jamroziak and Joanna Drozd-Sokołowska
Pharmaceuticals 2025, 18(10), 1461; https://doi.org/10.3390/ph18101461 - 28 Sep 2025
Viewed by 1093
Abstract
Lymphomas remain a significant cause of morbidity and mortality among patients living with HIV. Although the introduction of antiretroviral therapy has led to a reduction in the incidence of AIDS-related lymphomas (ARL) and an overall improvement in prognosis, these malignancies continue to pose [...] Read more.
Lymphomas remain a significant cause of morbidity and mortality among patients living with HIV. Although the introduction of antiretroviral therapy has led to a reduction in the incidence of AIDS-related lymphomas (ARL) and an overall improvement in prognosis, these malignancies continue to pose a considerable clinical challenge. Beyond the inherent complexity of lymphoma treatment itself, the management of comorbidities, particularly infections, represents a therapeutic obstacle. Here, we review the published evidence on ARL complicated by COVID-19. Despite the fact that nearly 800 million confirmed cases of SARS-CoV-2 infection have been reported so far, only five cases of ARL and COVID-19 have been published, among whom most patients experienced a mild course of SARS-CoV-2 infection, with only one case progressing to severe COVID-19 that required oxygen therapy and prolonged hospitalization. Additionally, we present another case of a 49-year-old male patient with newly diagnosed ARL, Epstein–Barr virus (EBV)-positive, diffuse large B-cell lymphoma, not otherwise specified, complicated by prolonged SARS-CoV-2 infection. Although initially asymptomatic, the patient subsequently experienced transient respiratory failure. Despite administration of molnupiravir, both SARS-CoV-2 antigen and RT-qPCR tests remained positive for a minimum of 113 days. The prolonged SARS-CoV-2 infection, in conjunction with other opportunistic infections, impeded the delivery of adequate chemotherapy dose intensity and contributed to disease progression and ultimately the patient’s death. This case and review of the literature underscores the diversity of the clinical course of SARS-CoV-2 infection in patients with ARL and highlights the associated challenges in delivering optimal anti-lymphoma therapy in those patients. Full article
(This article belongs to the Special Issue Advances in the Treatment of Leukemia, Lymphomas and Plasma Cell Disorders)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop